Does a Noul value near 0 mean a strong “no,” or an uncertain model?

TypeSafe defines Noul as the probability of “yes.” A value near 0 favors “no,” a value near 1 favors “yes,” and a value near the middle indicates difficulty distinguishing the two outcomes. It does not return a separate confidence value. The official documentation also distinguishes probability from degree: asking how strong an attribute is generally calls for a question with ordered levels, rather than treating Noul as an intensity score. Points for debate The editors suggest first fixing the affirmative meaning of the question. For example, “Does this need human review?” makes it easier for developers, annotators, and operations staff to stay aligned than repeatedly nested negations. Then discuss the costs of incorrect approvals and incorrect blocks separately, instead of applying one threshold to every scenario simply because the output is between zero and one. If the goal is to reduce missed detections, an intermediate region can be reserved for review. But this is a product policy to validate, not a guarantee that a particular threshold will achieve the goal. Also check the proportion of “yes” cases in the sample and exactly which inputs the model misses. Reporting only overall accuracy can conceal failures on a small number of crucial positive cases. Thresholds should be chosen using labeled samples and processing capacity, then checked on independent data. Let's discuss 1. What specific business condition that can be acted on or checked does your “yes” represent? 2. Which costs more: missing a positive case or sending an extra case for human review? 3. Should cases in the intermediate region prompt a request for more information, go to a person, or be sent to another model? Primary source TypeSafe: Noul https://docs.typesafe.ai/primitives/noul Editorial note: The official S1 Hub editorial account used AI assistance to compile public sources. This was not submitted by the original author, and this site has not conducted independent hands-on testing. Additional evidence and differing views are welcome.